A Dose-Finding Study Of Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
maximum tolerated dose
This will be defined as the dose at which fewer than 1:6 patients experiences a dose-limiting toxicity.
1 year
No
Jamie E. Chaft, MD
Principal Investigator
Memorial Sloan-Kettering Cancer Center
United States: Food and Drug Administration
12-279
NCT01836341
April 2013
April 2015
Name | Location |
---|---|
Memorial Sloan Kettering Cancer Center | New York, New York 10021 |
Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center | Sleepy Hollow, New York 10591 |
Memoral Sloan Kettering Cancer Center | Basking Ridge, New Jersey |
Memorial Sloan-Kettering Cancer Center @ Suffolk | Commack, New York 11725 |
Memorial Sloan-Kettering at Mercy Medical Center | Rockville Centre, New York |